| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||
Corrections to “Nonclassic Endogenous Regulators of Angiogenesis”
Four corrections need to be made to the above article (Ribatti D, Conconi MT, and Nussdorfer GG (2007)) Pharm Rev 59:185-205. These corrections are listed below.
1) The title in the Table of Contents and on page 185 should be revised to read as follows: “Nonclassic Endogenous Novel Regulators of Angiogenesis.”
2) A citation for Table 1 should be added immediately after the heading “6. Classic Endogenous Inhibitors of Angiogenesis” on page 189.
3) The following sentence should be added to the first full paragraph under “A. Erythropoietin” on page 190: “However, it is important to underline a strong-enough caution on the use of EPO in patients with malignancies, according to the directive of the US Food and Drug Administration.”
4) In Table 2 on page 198, the word “uncommon” should replace “unorthodox” in footnote d.
The online version will be corrected in departure from the print version.
We regret these errors and apologize for any confusion or inconvenience they may have caused.
| ||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
